Cellular immune response – Page 25 – Communicable Diseases Research

A Glimpse into the Diverse Cellular Immunity against SARS-CoV-2

Article

Published on 2021-07-272022-10-28
Journal: Vaccines [Category] COVID-19,

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Brief Communication

Published on 2021-07-262022-10-29
Journal: Nature Medicine [Category] COVID-19, Fulltext, SARS,

Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection

Communication

Published on 2021-07-262022-10-28
Journal: Pathogens [Category] COVID-19,

Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults

Article

Published on 2021-07-222022-10-28
Journal: Biomedicines [Category] COVID-19,

[키워드] Activation anti-S anti-S2 antibody assessment B-specific response BNT162b2 vaccine CD134 CD25 Cell Cellular immune response circulation Clinical data doses ELISA expression flow cytometry follicular healthcare worker humoral IgG immune response immune system immunized Immunological response involved memory memory cell memory T mRNA-based of BNT162b2 peptide Peripheral blood response responses against SARS-CoV-2 SARS-CoV-2 vaccination second dose significant increases in subject subset T follicular helper cells T helper T-specific response the vaccine vaccination Vaccine vaccine efficacy Vaccines was tested were measured
[DOI] 10.3390/biomedicines9080868 PMC 바로가기 [Article Type] Article

Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection

새로운 진핵생물 발현과 살모넬라 박토펙션을 혼합한 매우 실현 가능한 면역보호 멀티시스트론 SARS-CoV-2 백신 후보

Article

Published on 2021-07-222022-09-11
Journal: Journal of advanced research [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단,

[키워드] Analysis anti-SARS-CoV-2 immune responses Antibody titers antigen-specific antibody Antiviral CD4 CD8 Cell-mediated immunity Cellular immune response co-expression COVID-19 Cytometry demonstrated determine develop DNA domain effective Efficacy Efficiency elicited epitope Epitopes eukaryotic expressing expression feasible Flow flow cytometry Frame fused gene delivery heptad repeat highest humoral immune responses immunized mice immunofluorescence assay immunogenicity IMPROVE in vivo increase in investigated mechanism membrane protein mice mRNA Multicistronic expression multivalent vaccine neutralizing antibody titers nsp13 offer Open reading frame pandemic peptide polarization Protein protein expression raised RBD recall Receptor-binding domain recorded RNA robust Safe Salmonella SARS-CoV-2 SARS-CoV-2 gene SARS-CoV-2 genes SARS-CoV-2 neutralizing antibody SARS-CoV-2 protein SARS-CoV-2 proteins SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants sera Spike protein splenocyte splenocytes suggested T cell T cells targets Th1 Th1 response Th2 immunity the spike protein the vaccine Vaccine vaccine candidate vaccine construct variant variants were used western blot Western blot analysis
[DOI] 10.1016/j.jare.2021.07.007 PMC 바로가기 [Article Type] Article

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Clinical Trial

Published on 2021-07-102022-10-05
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상,

[키워드] 95% CI Abstract Administered adverse events age antibody assigned AstraZeneca baseline BNT162b2 booster Cellular immune response ChAdOx1-S control group Controlled trial COVID-19 dose Efficacy enrolled EudraCT FIVE French geometric mean titre Germany headache Heterologous Human IgG immune response immunoassay immunogenicity immunological individual injection site pain interferon-γ Intervention intervention group Intramuscular injection Local Mainz material men Mild moderate multicentre myalgia observation of BNT162b2 Open-label outcome Oxford participant phase 2 trial primary analysis Primary outcome pseudovirus neutralisation assay randomised Randomly RBD RBD protein reaction reactogenicity reactogenicity profile receive Receptor binding domain Registered reported robust safety analysis SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Event single dose Spain Spanish systemic adverse events translation Trimeric spike protein university hospital vaccination schedule women
[DOI] 10.1016/S0140-6736(21)01420-3 PMC 바로가기 [Article Type] Clinical Trial

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Articles

Published on 2021-07-082022-10-29
Journal: The Lancet Rheumatology [Category] COVID-19,

[키워드] 95% CI All participant B.1.1.7 variant BNT162b2 BNT162b2 vaccine Cellular immune response cellular response clinical effectiveness Cohort cohort study consecutive patient Control controls Coverage COVID-19 vaccine COVID-19 vaccine trials defined determine Diagnosis Dilution East eligible England evaluate evaluated extended interval females finding first dose foundation funding groups healthy control healthy controls humoral Humoral immunity IL-17 IL-2 IL-21 IL-23 immune response Immune-mediated inflammatory disease immunogenicity Immunosuppressant Immunosuppression individual inhibitors inhibitory interferon-γ IQR London lowest males median median age methotrexate monotherapy Necrosis neutralising antibody response Neutralising titre NHS of BNT162b2 participant Participants Patient Pfizer-BioNTech preserved Primary outcome receive receiving recruited Seven significantly lower single dose South spike glycoprotein spike-specific T-cell response study population the healthy the SARS-CoV-2 therapeutic Therapies Thoma TNF Trust vaccination vaccine immunogenicity Volunteer were excluded white wild-type SARS-CoV-2
[DOI] 10.1016/S2665-9913(21)00212-5 PMC 바로가기 [Article Type] Articles

Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations

Article

Published on 2021-07-052022-10-28
Journal: Vaccines [Category] COVID-19,

[키워드] addition adjuvant adjuvants aluminum Antibody Response candidate Cell Cellular immune response clinical trials coronavirus disease COVID-19 demonstrated domain effective vaccine Efficacy and safety elicited evaluated Formulation Frequency fused gel groups Head-to-head comparison hydroxide IgG IgG1 IgG2a Immune profile immune response immunogenicity MF59 mice Neutralizing antibodies neutralizing antibody no significant difference performed plant-based vaccine problem public health RBD RBD-Fc Receptor-binding domain Research responses Salmonella SARS-CoV-2 significantly increased subtype Subunit vaccine subunit vaccines tested Transmission vaccination Vaccine virus spread
[DOI] 10.3390/vaccines9070744 PMC 바로가기 [Article Type] Article

Humoral and cellular immune response to Plasmodium vivax VIR recombinant and synthetic antigens in individuals naturally exposed to P. vivax in the Republic of Korea

한국에서 P. vivax에 자연적으로 노출된 개인에서 Plasmodium vivax VIR 재조합 및 합성 항원에 대한 체액 및 세포 면역 반응

Research

Published on 2021-06-282024-08-08
Journal: Malaria Journal [Category] 말라리아,

[키워드] Cellular immune response humoral immune response Plasmodium vivax Variant interspersed repeats protein
[DOI] 10.1186/s12936-021-03810-2 PMC 바로가기 [Article Type] Research

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques

원숭이에서 SARS-CoV-2 B.1.351에 대한 Ad26.COV2.S의 보호 효능

Article

Published on 2021-06-232022-09-10
Journal: Nature [Category] MERS, SARS, 변종, 비임상, 유전자 메커니즘, 진단,

[키워드] Ad26 Ad26.COV2.S Ad26.COV2.S vaccine B.1.1.7 B.1.351 B.1.351 variant binding Bronchoalveolar lavage CAL.20C variants CD4 CD8 Cellular immune response comparable COVID-19 COVID-19 vaccine cross-react demonstrated Efficacy elicit elicited evade expresse Human humoral Humoral and cellular immune responses immune responses implication induce Infection macaque nasal swab nasal swabs Neutralizing antibodies neutralizing antibody P.1 PROTECT Protective provided rhesus macaque rhesus macaques robust SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sequenced South Africa Spike protein stabilized spike protein symptomatic symptomatic COVID-19 T cell T cell response These data Vaccine Vaccines virus virus replication viruses WA1/2020
[DOI] 10.1038/s41586-021-03732-8 PMC 바로가기 [Article Type] Article